(19)
(11) EP 0 648 228 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.04.2004 Bulletin 2004/17

(45) Mention of the grant of the patent:
04.11.1998 Bulletin 1998/45

(21) Application number: 93913278.3

(22) Date of filing: 02.06.1993
(51) International Patent Classification (IPC)7: C07K 16/26, C07K 14/575, C12P 21/08, G01N 33/577, G01N 33/68
(86) International application number:
PCT/GB1993/001173
(87) International publication number:
WO 1993/024531 (09.12.1993 Gazette 1993/29)

(54)

BNP ANTIBODY AND IMMUNOASSAY USING IT

BNP ANTIKÖRPER UND IMMUNOLOGISCHER NACHWEIS DER IHN BENUTZT

ANTICORPS DU BNP ET IMMUNO-DETECTION LES UTILISANT

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB IE IT LI LU NL SE

(30) Priority: 03.06.1992 GB 9211686

(43) Date of publication of application:
19.04.1995 Bulletin 1995/16

(73) Proprietor: MEDINNOVA SF
0027 Oslo (NO)

(72) Inventor:
  • HALL, Christian
    N-1335 Snaröya (NO)

(74) Representative: Dzieglewska, Hanna Eva et al
Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street
London EC4V 4EL
London EC4V 4EL (GB)


(56) References cited: : 
EP-A- 0 385 476
   
  • JAPANESE PATENTS ABSTRACTS (UNEXAMINED) Section Ch, Week 9207, Derwent Publications Ltd., London, GB; Class CH, AN 92-053618
  • CHEMICAL ABSTRACTS, vol. 114, no. 25, 24 June 1991, Columbus, Ohio, US; abstract no. 240736k, TOGASHI, KAZUYOSHI ET AL. 'A specific and highly sensitive radioimmunoassay of human brain natriuretic peptide' page 108 ;column L ;
  • J. CLIN. INVEST. vol. 87, no. 4, April 1991, AM. SOC. CLIN. INVEST., pages 1402 - 1412 M. MUKOYAMA ET AL. 'Brain natriuretic peptide as a novel cardiac hormone in humans' cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).